Zelluna Immunotherapy
Blood & Organ Banks · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ullernchausséen 64, Oslo, Oslo, 0379, No...Phone Number
+46 859478830Website
www.zelluna.comRevenue
$6.3 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
2
2
2
2
About Zelluna Immunotherapy
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property position enable it to pursue promising developments in the cell therapy field. Their mission is to transform cancer care by advancing innovative therapies that harness the immune system's capabilities.Explore more
Zelluna Immunotherapy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zelluna Immunotherapy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Zelluna Immunotherapy launches new products
Congratulate Masked Content for being promoted to Masked Content at Zelluna Immunotherapy
Check if Zelluna Immunotherapy has recently received funding, and reach out quickly before it becomes old news!
Zelluna Immunotherapy, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Zelluna Immunotherapy recently announced quarterly report
Check out if Zelluna Immunotherapy is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Zelluna Immunotherapy had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Zelluna Immunotherapy has new funding data
Recommended Actions
Reach out to Masked Content who joined Zelluna Immunotherapy as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Zelluna Immunotherapy is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Zelluna Immunotherapy is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Zelluna Immunotherapy.
Zelluna Immunotherapy financials insights
Gather financial insights about Zelluna Immunotherapy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$8.5M
Other Financing Round
$6M
Zelluna Immunotherapy Tech Stack
A closer look at the technologies used by Zelluna Immunotherapy
See more technologies
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Lateral Move
Executive Move
Executive Moves, Lateral Move
Promotion
Executive Move
Executive Moves, Promotion
Lateral Move
Executive Move
Executive Moves, Lateral Move
Zelluna Immunotherapy News & Media
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Zelluna ASA: First Quarter 2026 results
Oslo, 7 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the first quarter 2026.Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution
Oslo, 6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the first clinical site in the ZIMA-101 Phase 1 trial has now been activated.Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time)
Oslo, Norway, 4 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation of its first quarter 2026 results on Thursday, 7 May 2026. The start time has been corrected from 09:00 CEST to 08:30 CEST.
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zelluna Immunotherapy
Sign Up For FreeTo access detailed company insights
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property... Read More
